Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Krentz, A. J
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents?

Andrew J Krentz

Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK, a.j.Krentz{at}soton.ac.uk

It has been suggested that the association between type 2 diabetes and atherosclerotic cardiovascular disease might result from a shared antecedent — the `common soil' hypothesis. The antecedent could provide a fundamental link between type 2 diabetes and atherosclerosis via the metabolic (or insulin resistance) syndrome. The relative contributions of genes, fetal nutrition and environmental factors to this syndrome remain unclear. Although most patients with type 2 diabetes have insulin resistance, it is uncertain whether the insulin resistance-hyperinsulinaemia complex directly promotes atherogenesis, and whether type 2 diabetes and atheroma are connected via a common mediator such as central obesity, vascular endothelial dysfunction, or disordered lipid metabolism. Insulin sensitivity and cardiovascular risk may be influenced by adipocytokines (e.g. leptin and adiponectin), by excess fatty acids liberated from visceral fat, and inflammatory processes. Disturbances of the neuro-endocrine system, possibly mediated via visceral obesity, are also under investigation. Other putative links between type 2 diabetes and atheroma include polymorphisms in the genes for tumour necrosis factor-{alpha},insulin-like growth factor-1 promoter, and lamin A/C. Trials with certain cardioprotective agents including inhibitors of the renin-angiotensin-aldosterone system and statins can improve cardiovascular outcomes and protect against the development of type 2 diabetes, lending support to the common soil hypothesis.

Key Words: type 2 diabetes mellitus • cardiovascular disease • insulin resistance • adipocytes • PPAR- • thiazolidinediones.

References

  • Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002;287: 2570-81.[Abstract/Free Full Text]
  • Ginsberg HN Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Jarrett RJ Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg, or neither? Diabetologia 1984;26:99-102.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stern MP Diabetes and cardiovascular disease: the `common soil' hypothesis. Diabetes 1995;44:369-74.[Abstract]
  • Reaven GM Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.[Abstract]
  • Krentz AJ Insulin resistance. Oxford, Blackwell Science, 2002.
  • Haffner SM, Mykkänen L., Festa A., Burke J., Stern M. Insulin-resistant prediabetic subjects have more atherogenic risk factors that insulin sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.[Abstract/Free Full Text]
  • Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • Haffner SM, Lehto S., Ronnemaa T., Pyörälä K., Laasko M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
  • Evans JM, Wang J., Morris AD Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324:939-42.[Abstract/Free Full Text]
  • Turner RC, Millns H., Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8.[Abstract/Free Full Text]
  • Stratton IM, Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
  • Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med 1996;124:127-30.[Abstract/Free Full Text]
  • Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:949-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Khaw K.-T, Wareham N., Luben R. et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:15-18.[Abstract/Free Full Text]
  • Sudhir R., Mohan V. Postprandial hyperglycaemia in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1:105-16.[CrossRef][Medline] [Order article via Infotrieve]
  • Norhammer A., Tenerz A., Hamsten A., Efendic S., Ryden L., Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yudkin JS Managing the diabetic patient with acute myocardial infarction. Diabetic Med 1998;15:276-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haffner SM Primary prevention of cardiovascular disease in diabetes. Presentation at the American Diabetes Association 62nd Scientific Sessions, June 2002.
  • Wheeler DC Protecting the kidneys and cardiovascular system in type 2 diabetes. Br J Diabetes Vasc Dis 2002;2:77-9.[Free Full Text]
  • Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M-R., Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rett K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999;1(suppl 1):S8-S16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9.[Abstract/Free Full Text]
  • Wallace TM, Matthews DR The assessment of insulin resistance in man. Diabetic Med 2002;19:527-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Abe H., Yamada N., Kamata K. et al. Hypertension, hypertriglyceridaemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998;101:1784-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ford ES, Giles WH, Dietz EH Prevalence of the metabolic syndrome among US adults. Findings of the third national health and nutrition survey. JAMA 2002;287:356-9.[Abstract/Free Full Text]
  • Folsom AR Insulin resistance and cardiovascular disease. In: Reaven GM, Laws A. Insulin resistance - the metabolic syndrome X. Totowa, Human Press, 1999:333-46.
  • Stout RW Hyperinsulinemia and atherosclerosis. Diabetes 1996;45 (suppl 3):S45-S46.[Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malmberg K for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival in patients with diabetes mellitus. BMJ 1997;314:1512-15.[Abstract/Free Full Text]
  • Nordestgaard BG, Agerholm-Larson B., Stender S. Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits. Diabetologia 1997;40:512-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Williams SB, Cusco JA, Roddy MA et al. Impaired nitric oxide-mediated vasodilatation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardio 1996;27:567-74.[Abstract]
  • Arcaro G., Cretti A., Balzano S. et al. Insulin causes endothelial dysfunction in humans - sites and mechanisms. Circulation 2002;105:576-82.[Abstract/Free Full Text]
  • Ruige AJ, Assendelft WJJ, Dekker JM, Kostene PJ, Heine RJ, Bouter LM Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998;97:996-1001.[Abstract/Free Full Text]
  • Howard G., O'Leary DH, Zaccaro MS et al. Insulin sensitivity and atherosclerosis. Circulation 1996;93:1809-17.[Abstract/Free Full Text]
  • Haffner SM, D'Agostino Jr R., Mykkänen L. et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:562-8.[Abstract]
  • Bhopal R. Epidemic of cardiovascular disease in South Asians. BMJ 2002;324:625-6.[Free Full Text]
  • Peyser PA Genetic epidemiology of coronary heart disease. Epidemiol Rev 1997;19:80-90.[Free Full Text]
  • Mitchell BD, Imumorin IG Genetic determinants of diabetes and atherosclerosis. Curr Atheroscler Rep 2002;4:193-8.[Medline] [Order article via Infotrieve]
  • Pedersen O. Genetics of insulin resistance. Exp Clin Endocrinol Diab 1999;107:113-18.[Web of Science][Medline] [Order article via Infotrieve]
  • Björntorp P. Thrifty genes and human obesity. Are we chasing ghosts? Lancet 2001;358:1006-08.[CrossRef][Medline] [Order article via Infotrieve]
  • Gerich JE Is insulin resistance the principal cause of type 2 diabetes? Diabetes Obes Metabol 1999;1:257-63.[CrossRef]
  • Eriksson J., Fransilla-Kallunki A., Ekstrand A. et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-43.[Abstract]
  • Vauhkonen I., Niskanen L., Vanninen E., Kainulainen S., Uusitupa M., Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. J Clin Invest 1998;101:86-96.[Web of Science][Medline] [Order article via Infotrieve]
  • Haffner SM, Valdez RA, Hazuda HH, Mitchell BD, Morales PA, Stern MP Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992;41:715-22.[Abstract]
  • Meigs J., D'Agostino Sr, RB, Wilson PWF, Cupples A., Nathan D., Singer DE Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997;46:1594-600.[Abstract]
  • Groop LC, Ekstrand A., Forsblom C. et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:642-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bonora E., Targher G., Alberiche G. et al. Predictors of insulin sensitivity in type 2 diabetes. Diabetic Med 2002;19:535-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marenberg ME, Risch N., Berkman LF et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.[Abstract/Free Full Text]
  • Day INM, Wilson DI Genetics and cardiovascular risk. BMJ 2001;323: 1409-12.[Free Full Text]
  • Edmunds E., Lip GY Cardiovascular disease in women: the cardiologist's perspective. Q J Med 2000;93:134-45.
  • Sattar N., Greer IA Pregnancy complications and maternal cardiovascular risk. BMJ 2002;325:157-60.[Free Full Text]
  • Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Phillips DIP, Barker DJP. The thrifty phenotype hypothesis. In: Leslie RDG (ed). Causes of diabetes. Chichester, John Wiley & Sons, 1993.
  • Marmot M. Aetiology of coronary heart disease. BMJ 2001;323:1261-2.[Free Full Text]
  • Hopkinson ZE, Sattar N., Fleming R., Greer IA Polycystic ovarian syndrome; the metabolic syndrome comes to gynaecology. BMJ 1998;317: 329-32.[Free Full Text]
  • Holte J., Gennarelli G., Wide L., Lithell H., Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-50.[Abstract/Free Full Text]
  • Diamanti-Kandarakis E., Bergeile A. The influence of obesity on hyperandrogenism and infertility in the female. Obes Rev 2001;2:231-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Kahn BB, Flier JS Obesity and insulin resistance. J Clin Invest 2000;106: 473-81.[Web of Science][Medline] [Order article via Infotrieve]
  • Montague CT, O'Rahilly S. The perils of portliness. Diabetes 2000; 49:883-8.[Abstract]
  • Tuomilehto J., Lindstrom J., Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
  • Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Pinkney J. Implications of obesity for diabetes and coronary heart disease in clinical practice. Br J Diabetes Vasc Dis 2001;1:103-06.[Abstract/Free Full Text]
  • Reaven GM, Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.[Free Full Text]
  • Rocchini AP Childhood obesity and a diabetes epidemic. N Engl J Med 2002;346:854-5.[Free Full Text]
  • Tounian P., Aggoun Y., Dubern B. et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001;358:1400-04.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Reaven GM The fourth Musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 1995;38:3-13.[Web of Science][Medline] [Order article via Infotrieve]
  • Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;45:3-10.
  • Paolisso G., Howard BV Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes. Diabetic Med 1998;15:360-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McGarry JD, Dobbins RL Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fagot-Campagna A., Balkau B., Simon D. et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998;27:808-13.[Abstract/Free Full Text]
  • Steinberg HO, Tarshoby M., Monestel R. et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilatation. J Clin Invest 1997;100:1230-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Pirro M., Mauriège P., Tchernof A. et al. Plasma free fatty acid levels and the risk of ischaemic heart disease in men: prospective results from the Québec Cardiovascular Study. Atherosclerosis 2002;160:377-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stears AJ, Byrne CD Adipocyte metabolism and the metabolic syndrome. Diabetes Obes Metabol 2001;3:171-6.[CrossRef]
  • Perry CJ, Sattar N., Petrie JR Adipose tissue: passive sump or active pump? Br J Diabetes Vasc Dis 2001;1:110-14.[Abstract/Free Full Text]
  • Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104:3052-6.[Abstract/Free Full Text]
  • Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;8:941-6.
  • Auwerx J. PPAR-, the ultimate thrifty gene. Diabetologia 1999;42: 1033-49.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999;16:179-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marten Fmac, Visseren FLJ, Lemay J., de Koning EJP, Rabelink TJ Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pradhan AD, Manson JE, Rifal N., Buring JE, Ridker PM C-reactive protein and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327-34.[Abstract/Free Full Text]
  • Barzilay JI, Abraham L., Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-9.[Abstract/Free Full Text]
  • Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.[Free Full Text]
  • Pepys MB, Berger A. The renaissance of C-reactive protein. BMJ 2001; 322:4-5.[Free Full Text]
  • Duncan BB, Schmidt ML Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paolo Med J 2001;3: 122-7.
  • O'Rahilly SP The metabolic syndrome: all in the mind? Diabetic Med 1999;16:355-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Björntorp P. Neuroendocrine disturbances as a cause of insulin resistance. Diabetes Metab Res Rev 1999;15:427-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Andrews RC, Walker BR Glucocorticoids and insulin resistance: old hormone, new targets. Clin Sci 1999;96:513-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parulkar AA, Pendergrass ML, Granda-Ayala R., Lee TR, Fonseca VA Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134:61-71.[Abstract/Free Full Text]
  • Yusuf S., Gerstein H., Hoogwerff B., Pogue J. et al. for the HOPE study investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.[Abstract/Free Full Text]
  • Hansson L., Lindholmn LH, Niskanen L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713-20.[Abstract/Free Full Text]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ballantyne CM, Olsson AG, Cook TJ et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastain in 4S. Circulation 2001; 104:3046-51.[Abstract/Free Full Text]
  • Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.[Abstract/Free Full Text]
  • Massie BM Obesity and heart failure - risk factor or mechanism? N Engl J Med 2002;347:358-9.[Free Full Text]
  • Permutt MA, Bernal-Mizrachi E., Inoue H. Calpain 10: the first positional cloning of a gene for type 2 diabetes? J Clin Invest 2000;106:819-21.[Web of Science][Medline] [Order article via Infotrieve]
  • Menzel S. Genetic and molecular analyses of complex genetic disorders: genetic linkage. Ann N Y Acad Sci 2002;967:249-57.[Web of Science][Medline] [Order article via Infotrieve]
  • Vaessen N., Heutink P., Janssen JA et al. A polymorphism in the gene for IGF-1: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.[Abstract/Free Full Text]
  • Vaessen N., Janssen JA, Heutink P. et al. Association between genetic variation in the gene for insulin-like growth factor-1 and low birth-weight. Lancet 2002;359:10336-7.
  • Aitman TJ CD36, insulin resistance, and coronary heart disease. Lancet 2001;357:686-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Koishi R., Ando Y., Ono M. et al. Angptl3 regulates lipid metabolism in mice. Nature Genet 2002;30:151-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Glass GK Antiatherogenic effects of thiazolidinediones? Arterioscler Thromb Vasc Biol 2001;21:295-6.[Free Full Text]
  • Hseuh WA, Law RE PPAR-{gamma} and atherosclerosis. Effect on cell growth and movement. Arterioscler Thromb Vasc Biol 2001;21:1891-5.[Abstract/Free Full Text]
  • Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 5, 370-378 (2002)
DOI: 10.1177/14746514020020050501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
C. Day
Metabolic syndrome, or What you will: definitions and epidemiology
Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 32 - 38.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Krentz, A. J
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?